Scribe Therapeutics reaches second milestone in Lilly collaboration
Scribe Therapeutics reported a second research milestone in its in vivo CRISPR collaboration with Eli Lilly, advancing work using its X-Editor platform for neurological and neuromuscular gene therapies; specific targets and financial details were not disclosed and programs remain investigational.
Why it mattersScribe's X-Editor milestone with Lilly for neurological gene therapies de-risks in vivo CRISPR, prompting investors to accelerate funding.